LECITHIN: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Lecithin is a mixture of fats that are essential to cells in the human body. It can be found in many foods, including soybeans and egg yolks.

In the diet, lecithin is the main source of choline, a nutrient similar to the B vitamins. Lecithin is converted into acetylcholine, a substance that transmits nerve impulses.

People use lecithin for Alzheimer disease and dementia, Parkinson disease, and many other conditions, but there is no good scientific evidence to support these uses.

Uses & Effectiveness

Likely InEffective for

Alzheimer disease. Taking lecithin by mouth doesn't seem to improve mental abilities or slow the progression of Alzheimer disease.

There is interest in using Lecithin for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

Side Effects

When taken by mouth: Lecithin is commonly consumed in foods. It is likely safe when taken as a supplement in doses up to 30 grams daily for up to 6 weeks. It can cause some side effects including diarrhea, nausea, stomach pain, or fullness.

When applied to the skin: Lecithin is likely safe for most adults.

Special Precautions and Warnings

Pregnancy and breast-feeding: Lecithin is commonly consumed in foods. There isn't enough reliable information to know if lecithin is safe to use in larger amounts as medicine when pregnant or breast-feeding. Stay on the safe side and stick to food amounts.

Egg or soy allergy: Lecithin might cause allergic reactions in people with egg or soy allergies.

Interactions

We currently have no information for LECITHIN overview.

Dosing

Lecithin has most often been used by adults in doses of 20-30 grams by mouth daily. Speak with a healthcare provider to find out what dose might be best for a specific condition.

View References

REFERENCES:

Eckart, J., Neeser, G., Wengert, P., and Adolph, M. [Side effects and complications of parenteral nutrition]. Infusionstherapie. 1989;16(5):204-213. View abstract.

ECKENHOFF, J. E. and OECH, S. R. The effects of narcotics and antagonists upon respiration and circulation in man. A review. Clin Pharmacol Ther 1960;1:483-524. View abstract.

Faden, A. I., Jacobs, T. P., Mougey, E., and Holaday, J. W. Endorphins in experimental spinal injury: therapeutic effect of naloxone. Ann Neurol. 1981;10(4):326-332. View abstract.

Finkle, B. S., McCloskey, K. L., and Goodman, L. S. Diazepam and drug-associated deaths. A survey in the United States and Canada. JAMA 8-3-1979;242(5):429-434. View abstract.

Fischer, K. F., Lees, J. A., and Newman, J. H. Hypoglycemia in hospitalized patients. Causes and outcomes. N.Engl J Med 11-13-1986;315(20):1245-1250. View abstract.

Flacke, J. W., Flacke, W. E., and Williams, G. D. Acute pulmonary edema following naloxone reversal of high-dose morphine anesthesia. Anesthesiology 1977;47(4):376-378. View abstract.

Flamm, E. S., Young, W., Collins, W. F., Piepmeier, J., Clifton, G. L., and Fischer, B. A phase I trial of naloxone treatment in acute spinal cord injury. J Neurosurg. 1985;63(3):390-397. View abstract.

Foy, A., March, S., and Drinkwater, V. Use of an objective clinical scale in the assessment and management of alcohol withdrawal in a large general hospital. Alcohol Clin Exp Res 1988;12(3):360-364. View abstract.

Fulop, M. Alcoholic ketoacidosis. Endocrinol Metab Clin North Am 1993;22(2):209-219. View abstract.

Funderburk, F. R., Allen, R. P., and Wagman, A. M. Residual effects of ethanol and chlordiazepoxide treatments for alcohol withdrawal. J Nerv Ment.Dis 1978;166(3):195-203. View abstract.

Gaby, A. R. Natural approaches to epilepsy. Altern.Med Rev. 2007;12(1):9-24. View abstract.

Gibberd, F. B., Nicholls, A., and Wright, M. G. The influence of folic acid on the frequency of epileptic attacks. Eur J Clin Pharmacol. 1981;19(1):57-60. View abstract.

Gillman, M. A. and Lichtigfeld, F. J. Minimal sedation required with nitrous oxide-oxygen treatment of the alcohol withdrawal state. Br J Psychiatry 1986;148:604-606. View abstract.

GLATT, M. M., GEORGE, H. R., and FRISCH, E. P. Controlled trial of chlormethiazole in treatment of the alcoholic withdrawal phase. Br Med J 8-14-1965;2(5458):401-404. View abstract.

Gokhale, L. B. Curative treatment of primary (spasmodic) dysmenorrhoea. Indian J Med Res. 1996;103:227-231. View abstract.

Golbert, T. M., Sanz, C. J., Rose, H. D., and Leitschuh, T. H. Comparative evaluation of treatments of alcohol withdrawal syndromes. JAMA 7-10-1967;201(2):99-102. View abstract.

Goldfarb, S., Cox, M., Singer, I., and Goldberg, M. Acute hyperkalemia induced by hyperglycemia: hormonal mechanisms. Ann Intern Med 1976;84(4):426-432. View abstract.

Grant, R. H. and Stores, O. P. Folic acid in folate-deficient patients with epilepsy. Br Med J 12-12-1970;4(5736):644-648. View abstract.

Greenblatt, D. J., Allen, M. D., Noel, B. J., and Shader, R. I. Acute overdosage with benzodiazepine derivatives. Clin Pharmacol Ther 1977;21(4):497-514. View abstract.

Gregory, M. E. Reviews of the progress of Dairy Science. Water-soluble vitamins in milk and milk products. J Dairy Res 1975;42(1):197-216. View abstract.

Groeger, J. S., Carlon, G. C., and Howland, W. S. Naloxone in septic shock. Crit Care Med 1983;11(8):650-654. View abstract.

GRUENWALD, F., HANLON, T. E., WACHSLER, S., and KURLAND, A. A. A comparative study of promazine and triflupromazine in the treatment of acute alcoholism. Dis Nerv Syst. 1960;21:32-38. View abstract.

Gurll, N. J., Reynolds, D. G., Vargish, T., and Lechner, R. Naloxone without transfusion prolongs survival and enhances cardiovascular function in hypovolemic shock. J Pharmacol Exp Ther 1982;220(3):621-624. View abstract.

Hart, W. T. A comparison of promazine and paraldehyde in 175 cases of alcohol withdrawal. Am J Psychiatry 1961;118:323-327.

Hazell, A. S., Todd, K. G., and Butterworth, R. F. Mechanisms of neuronal cell death in Wernicke's encephalopathy. Metab Brain Dis 1998;13(2):97-122. View abstract.

Helphingstine, C. J. and Bistrian, B. R. New Food and Drug Administration requirements for inclusion of vitamin K in adult parenteral multivitamins. JPEN J Parenter.Enteral Nutr 2003;27(3):220-224. View abstract.

Hillbom, M., Tokola, R., Kuusela, V., Karkkainen, P., Kalli-Lemma, L., Pilke, A., and Kaste, M. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol 1989;6(3):223-226. View abstract.

Hoffman, R. S. and Goldfrank, L. R. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. JAMA 8-16-1995;274(7):562-569. View abstract.

Hojer, J. Severe metabolic acidosis in the alcoholic: differential diagnosis and management. Hum Exp Toxicol 1996;15(6):482-488. View abstract.

Horwitz, R. I., Gottlieb, L. D., and Kraus, M. L. The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome. Results of a randomized clinical trial. Arch Intern Med 1989;149(5):1089-1093. View abstract.

Horwitz, S. J., Klipstein, F. A., and Lovelace, R. E. Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant drug therapy. Lancet 3-16-1968;1(7542):563-565. View abstract.

Hosein, I. N., de, Freitas R., and Beaubrun, M. H. Intramuscular/oral lorazepam in acute alcohol withdrawal and incipient delirium tremens. Curr Med Res Opin. 1978;5(8):632-636. View abstract.

Hosein, I. N., de, Freitas R., and Beaubrun, M. H. Intramuscular/oral lorazepam in acute alcohol withdrawal and incipient delirium tremens. West Indian Med J 1979;28(1):45-48. View abstract.

Huey, L. Y., Janowsky, D. S., Mandell, A. J., Judd, L. L., and Pendery, M. Preliminary studies on the use of thyrotropin releasing hormone in manic states, depression, and the dysphoria of alcohol withdrawal. Psychopharmacol.Bull 1975;11(1):24-27. View abstract.

Jackson, R. and Teece, S. Best evidence topic report. Oral or intravenous thiamine in the emergency department. Emerg.Med J 2004;21(4):501-502. View abstract.

Jensen, O. N. and Olesen, O. V. Subnormal serum folate due to anticonvulsive therapy. A double-blind study of the effect of folic acid treatment in patients with drug-induced subnormal serum folates. Arch Neurol. 1970;22(2):181-182. View abstract.

Johnson, K. A., Bernard, M. A., and Funderburg, K. Vitamin nutrition in older adults. Clin Geriatr.Med 2002;18(4):773-799. View abstract.

Jurgenson, C. T., Begley, T. P., and Ealick, S. E. The structural and biochemical foundations of thiamin biosynthesis. Annu.Rev Biochem 2009;78:569-603. View abstract.

Kaim, S. C., Klett, C. J., and Rothfeld, B. Treatment of the acute alcohol withdrawal state: a comparison of four drugs. Am J Psychiatry 1969;125(12):1640-1646. View abstract.

Kearsley, J. H. and Musso, A. F. Hypothermia and coma in the Wernicke-Korsakoff syndrome. Med J Aust. 11-1-1980;2(9):504-506. View abstract.

Kodentsova, V. M. [Excretion of vitamins and their metabolites in urine as criteria of human vitamin status]. Vopr.Med Khim. 1992;38(4):33-37. View abstract.

Koppi, S., Eberhardt, G., Haller, R., and Konig, P. Calcium-channel-blocking agent in the treatment of acute alcohol withdrawal--caroverine versus meprobamate in a randomized double-blind study. Neuropsychobiology 1987;17(1-2):49-52. View abstract.

Kotani, N., Oyama, T., Sakai, I., Hashimoto, H., Muraoka, M., Ogawa, Y., and Matsuki, A. Analgesic effect of a herbal medicine for treatment of primary dysmenorrhea--a double-blind study. Am.J Chin Med 1997;25(2):205-212. View abstract.

Kramp, P. and Rafaelsen, O. J. Delirium tremens: a double-blind comparison of diazepam and barbital treatment. Acta Psychiatr.Scand 1978;58(2):174-190. View abstract.

Krauss, S. Post-hypoglycaemic encephalopathy. Br Med J 6-5-1971;2(5761):591. View abstract.

Krishel, S., SaFranek, D., and Clark, R. F. Intravenous vitamins for alcoholics in the emergency department: a review. J Emerg.Med 1998;16(3):419-424. View abstract.

Kristensen, C. P., Rasmussen, S., Dahl, A., and et al. The withdrawal syndrome scale for alcohol and related psychoactive drugs: total scores for guidelines for treatment with phenobarbital. Nord Psykiatr Tidsskr 1986;40:139-146.

LATIES, V. G., LASAGNA, L., GROSS, G. M., HITCHMAN, I. L., and FLORES, J. A controlled trial on chlorpromazine and promazine in the management of delirium tremens. Q.J Stud.Alcohol 1958;19(2):238-243. View abstract.

Lee, B. Y., Yanamandra, K., and Bocchini, J. A., Jr. Thiamin deficiency: a possible major cause of some tumors? (review). Oncol Rep. 2005;14(6):1589-1592. View abstract.

Levin, E. R., Sharp, B., Drayer, J. I., and Weber, M. A. Severe hypertension induced by naloxone. Am J Med Sci 1985;290(2):70-72. View abstract.

Lichtigfeld, F. J. and Gillman, M. A. Analgesic nitrous oxide for alcohol withdrawal is better than placebo. Int J Neurosci. 1989;49(1-2):71-74. View abstract.

Lichtigfeld, F. J. and Gillman, M. A. The effect of placebo in the alcohol withdrawal state. Alcohol Alcohol 1989;24(2):109-112. View abstract.

Liebaldt, G. P. and Schleip, I. 6. Apallic syndrome following protracted hypoglycemia. Monogr Gesamtgeb.Psychiatr.Psychiatry Ser. 1977;14:37-43. View abstract.

Macias-Matos, C., Rodriguez-Ojea, A., Chi, N., Jimenez, S., Zulueta, D., and Bates, C. J. Biochemical evidence of thiamine depletion during the Cuban neuropathy epidemic, 1992-1993. Am J Clin Nutr 1996;64(3):347-353. View abstract.

Mahoney, D. J., Parise, G., and Tarnopolsky, M. A. Nutritional and exercise-based therapies in the treatment of mitochondrial disease. Curr Opin Clin Nutr Metab Care 2002;5(6):619-629. View abstract.

Malcolm, R., Ballenger, J. C., Sturgis, E. T., and Anton, R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry 1989;146(5):617-621. View abstract.

Malouf, R. and Brust, J. C. Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol. 1985;17(5):421-430. View abstract.

Manore, M. M. Effect of physical activity on thiamine, riboflavin, and vitamin B-6 requirements. Am J Clin Nutr 2000;72(2 Suppl):598S-606S. View abstract.

Martin, P. R., McCool, B. A., and Singleton, C. K. Molecular genetics of transketolase in the pathogenesis of the Wernicke-Korsakoff syndrome. Metab Brain Dis 1995;10(1):45-55. View abstract.

Martin, W. R. Naloxone. Ann Intern Med 1976;85(6):765-768. View abstract.

Massman, J. E. and Tipton, D. M. Signs and symptoms assessment: a guide for the treatment of the alcohol withdrawal syndrome. J Psychoactive Drugs 1988;20(4):443-444. View abstract.

Mattson, R. H., Gallagher, B. B., Reynolds, E. H., and Glass, D. Folate therapy in epilepsy. A controlled study. Arch Neurol. 1973;29(2):78-81. View abstract.

Mayo-Smith, M. F. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 7-9-1997;278(2):144-151. View abstract.

McEntee, W. J. Wernicke's encephalopathy: an excitotoxicity hypothesis. Metab Brain Dis 1997;12(3):183-192. View abstract.

Meador, K., Loring, D., Nichols, M., Zamrini, E., Rivner, M., Posas, H., Thompson, E., and Moore, E. Preliminary findings of high-dose thiamine in dementia of Alzheimer's type. J Geriatr.Psychiatry Neurol. 1993;6(4):222-229. View abstract.

Melamed, E. Reactive hyperglycaemia in patients with acute stroke. J Neurol.Sci 1976;29(2-4):267-275. View abstract.

Mezadri, T., Fernandez-Pachon, M. S., Villano, D., Garcia-Parrilla, M. C., and Troncoso, A. M. [The acerola fruit: composition, productive characteristics and economic importance]. Arch Latinoam.Nutr 2006;56(2):101-109. View abstract.

Michaelis, L. L., Hickey, P. R., Clark, T. A., and Dixon, W. M. Ventricular irritability associated with the use of naloxone hydrochloride. Two case reports and laboratory assessment of the effect of the drug on cardiac excitability. Ann Thorac.Surg 1974;18(6):608-614. View abstract.

MOROZ, R. and RECHTER, E. MANAGEMENT OF PATIENTS WITH IMPENDING AND FULL-BLOWN DELIRIUM TREMENS. Psychiatr.Q. 1964;38:619-626. View abstract.

Muller, D. J. A comparison of three approaches to alcohol-withdrawal states. South.Med J 1969;62(4):495-496. View abstract.

Nakada, T. and Knight, R. T. Alcohol and the central nervous system. Med Clin North Am 1984;68(1):121-131. View abstract.

Nakamura, J. [Development of therapeutic agents for diabetic neuropathies]. Nippon Rinsho 2005;63 Suppl 6:614-621. View abstract.

Nichols, M. E., Meador, K. J., Loring, D. W., and Moore, E. E. Preliminary findings on the clinical effects of high dose thiamine in alcohol related cognitive disorders.

Nolan, K. A., Black, R. S., Sheu, K. F., Langberg, J., and Blass, J. P. A trial of thiamine in Alzheimer's disease. Arch Neurol. 1991;48(1):81-83. View abstract.

Okudaira, K. [Late withdrawal syndrome]. Ryoikibetsu.Shokogun.Shirizu. 2003;(40):429-431. View abstract.

Oppenheimer, S. M., Hoffbrand, B. I., Oswald, G. A., and Yudkin, J. S. Diabetes mellitus and early mortality from stroke. Br Med J (Clin Res Ed) 10-12-1985;291(6501):1014-1015. View abstract.

Palestine, M. L. and Alatorre, E. Control of acute alcoholic withdrawal symptoms: a comparative study of haloperidol and chlordiazepoxide. Curr Ther Res Clin Exp 1976;20(3):289-299. View abstract.

Palsson, A. The efficacy of early chlormethiazole medication in the prevention of delirium tremens. A retrospective study of the outcome of different drug treatment strategies at the Helsingborg psychiatric clinics, 1975-1980. Acta Psychiatr.Scand Suppl 1986;329:140-145. View abstract.

Poppell, T. D., Keeling, S. D., Collins, J. F., and Hassell, T. M. Effect of folic acid on recurrence of phenytoin-induced gingival overgrowth following gingivectomy. J Clin Periodontol. 1991;18(2):134-139. View abstract.

Poutanen, P. Experience with carbamazepine in the treatment of withdrawal symptoms in alcohol abusers. Br J Addict.Alcohol Other Drugs 1979;74(2):201-204. View abstract.

Proctor, M. L. and Farquhar, C. M. Dysmenorrhoea. Clin Evid (Online) 2007;2007 View abstract.

Proctor, M. L. and Murphy, P. A. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane.Database.Syst.Rev 2001;(3):CD002124. View abstract.

Prough, D. S., Roy, R., Bumgarner, J., and Shannon, G. Acute pulmonary edema in healthy teenagers following conservative doses of intravenous naloxone. Anesthesiology 1984;60(5):485-486. View abstract.

Pulsinelli, W. A., Levy, D. E., Sigsbee, B., Scherer, P., and Plum, F. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med 1983;74(4):540-544. View abstract.

Pulsinelli, W. A., Waldman, S., Rawlinson, D., and Plum, F. Moderate hyperglycemia augments ischemic brain damage: a neuropathologic study in the rat. Neurology 1982;32(11):1239-1246. View abstract.

Rado, J. P. Effect of mineralocorticoids on the paradoxical glucose-induced hyperkalemia in nondiabetic patients with selective hypoaldosteronism. Res Commun Chem Pathol.Pharmacol 1977;18(2):365-368. View abstract.

Radouco-Thomas, S., Garcin, F., Guay, D., Marquis, P. A., Chabot, F., Huot, J., Chawla, S., Forest, J. C., Martin, S., Stewart, G., and . Double blind study on the efficacy and safety of tetrabamate and chlordiazepoxide in the treatment of the acute alcohol withdrawal syndrome. Prog.Neuropsychopharmacol.Biol Psychiatry 1989;13(1-2):55-75. View abstract.

Ralston, A. J., Snaith, R. P., and Hinley, J. B. Effects of folic acid on fit-frequency and behaviour in epileptics on anticonvulsants. Lancet 4-25-1970;1(7652):867-868. View abstract.

Ranganathan, L. N. and Ramaratnam, S. Vitamins for epilepsy. Cochrane.Database.Syst.Rev 2005;(2):CD004304. View abstract.

Reuler, J. B., Girard, D. E., and Cooney, T. G. Current concepts. Wernicke's encephalopathy. N.Engl J Med 4-18-1985;312(16):1035-1039. View abstract.

Rieck, J., Halkin, H., Almog, S., Seligman, H., Lubetsky, A., Olchovsky, D., and Ezra, D. Urinary loss of thiamine is increased by low doses of furosemide in healthy volunteers. J Lab Clin Med 1999;134(3):238-243. View abstract.

Rindi, G. and Laforenza, U. Thiamine intestinal transport and related issues: recent aspects. Proc Soc Exp Biol Med 2000;224(4):246-255. View abstract.

Ritson, B. and Chick, J. Comparison of two benzodiazepines in the treatment of alcohol withdrawal: effects on symptoms and cognitive recovery. Drug Alcohol Depend. 1986;18(4):329-334. View abstract.

Robinson, B. H., MacKay, N., Chun, K., and Ling, M. Disorders of pyruvate carboxylase and the pyruvate dehydrogenase complex. J Inherit.Metab Dis 1996;19(4):452-462. View abstract.

Robinson, B. J., Robinson, G. M., Maling, T. J., and Johnson, R. H. Is clonidine useful in the treatment of alcohol withdrawal? Alcohol Clin Exp Res 1989;13(1):95-98. View abstract.

Rock, P., Silverman, H., Plump, D., Kecala, Z., Smith, P., Michael, J. R., and Summer, W. Efficacy and safety of naloxone in septic shock. Crit Care Med 1985;13(1):28-33. View abstract.

Rodriguez-Martin, J. L., Lopez-Arrieta, J. M., and Qizilbash, N. Thiamine for Alzheimer's disease. Cochrane Database.Syst.Rev 2000;(2):CD001498. View abstract.

Schmitz, R. E. The prevention and management of the acute alcohol withdrawal syndrome by the use of alcohol. Curr Alcohol 1977;3:575-589.

Seibert, D. G. Reversible decerebrate posturing secondary to hypoglycemia. Am J Med 1985;78(6 Pt 1):1036-1037. View abstract.

Barbeau, A. Emerging treatments: replacement therapy with choline or lecithin in neurological diseases. Can.J.Neurol.Sci. 1978;5(1):157-160. View abstract.

Barbeau, A. Lecithin in neurologic disorders. N.Engl.J Med 7-27-1978;299(4):200-201. View abstract.

Bellelli, A., Giomini, M., Giuliani, A. M., Giustini, M., Lorenzon, I., Rusconi, V., Sezzi, M. L., Trotta, E., and Belleli, L. Antitumor effect and cardiotoxicity of a doxorubicin-lecithin association. Anticancer Res 1988;8(1):177-186. View abstract.

Benton, D. and Donohoe, R. T. The influence on cognition of the interactions between lecithin, carnitine and carbohydrate. Psychopharmacology (Berl) 2004;175(1):84-91. View abstract.

Branconnier, R. J., Dessain, E. C., Cole, J. O., and McNiff-Langille, M. E. An analysis of dose-response of plasma choline to oral lecithin. Biol.Psychiatry 1984;19(5):765-770. View abstract.

Brinkman, S. D., Pomara, N., Goodnick, P. J., Barnett, N., and Domino, E. F. A dose-ranging study of lecithin in the treatment of primary degenerative dementia (Alzheimer disease). J Clin Psychopharmacol. 1982;2(4):281-285. View abstract.

Caine, E. D. Cholinomimetic treatment fails to improve memory disorders. N.Engl.J Med 9-4-1980;303(10):585-586. View abstract.

Canter, N. L., Hallett, M., and Growdon, J. H. Lecithin does not affect EEG spectral analysis or P300 in Alzheimer disease. Neurology 1982;32(11):1260-1266. View abstract.

Chuaqui, P. and Levy, R. Fluctuations of free choline levels in plasma of Alzheimer patients receiving lecithin: preliminary observations. Br.J.Psychiatry 1982;140:464-469. View abstract.

Crapper McLachlan, D. R., Dalton, A. J., Kruck, T. P., Bell, M. Y., Smith, W. L., Kalow, W., and Andrews, D. F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 6-1-1991;337(8753):1304-1308. View abstract.

Davidson, M., Mohs, R. C., Hollander, E., Zemishlany, Z., Powchik, P., Ryan, T., and Davis, K. L. Lecithin and piracetam in Alzheimer's disease. Biol.Psychiatry 1987;22(1):112-114. View abstract.

Duffy, F. H., McAnulty, G., Albert, M., Durwen, H., and Weintraub, S. Lecithin: absence of neurophysiologic effect in Alzheimer's disease by EEG topography. Neurology 1987;37(6):1015-1019. View abstract.

Dysken, M. W., Fovall, P., Harris, C. M., Davis, J. M., and Noronha, A. Lecithin administration in Alzheimer dementia. Neurology 1982;32(10):1203-1204. View abstract.

Foster, N. L., Petersen, R. C., Gracon, S. I., and Lewis, K. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group. Dementia 1996;7(5):260-266. View abstract.

Gauthier, S., Bouchard, R., Bacher, Y., Bailey, P., Bergman, H., Carrier, L., Charbonneau, R., Clarfield, M., Collier, B., Dastoor, D., and . Progress report on the Canadian Multicentre Trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease. Can.J Neurol.Sci 1989;16(4 Suppl):543-546. View abstract.

Gauthier, S., Bouchard, R., Lamontagne, A., Bailey, P., Bergman, H., Ratner, J., Tesfaye, Y., Saint-Martin, M., Bacher, Y., Carrier, L., and . Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl.J Med 5-3-1990;322(18):1272-1276. View abstract.

Gelenberg, A. J., Doller-Wojcik, J. C., and Growdon, J. H. Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am J Psychiatry 1979;136(6):772-776. View abstract.

Growdon, J. H., Wheeler, S., and Graham, H. N. Plasma choline responses to lecithin-enriched soup. Psychopharmacol.Bull 1984;20(3):603-606. View abstract.

Hallett, M., Canter, N., and Growdon, J. Neurophysiologic Parameters in Alzheimer Disease: Effect of Lecithin. Neurology 1982;32(2):a126.

Halliday, H. L., McClure, G., Reid, M. M., Lappin, T. R., Meban, C., and Thomas, P. S. Controlled trial of artificial surfactant to prevent respiratory distress syndrome. Lancet 3-3-1984;1(8375):476-478. View abstract.

Holford, N. H. and Peace, K. The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials. Eur J Clin Pharmacol 1994;47(1):17-23. View abstract.

Jackson, I. V., Nuttall, E. A., Ibe, I. O., and Perez-Cruet, J. Treatment of tardive dyskinesia with lecithin. Am J Psychiatry 1979;136(11):1458-1460. View abstract.

Kaye, W. H., Sitaram, N., Weingartner, H., Ebert, M. H., Smallberg, S., and Gillin, J. C. Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment. Biol.Psychiatry 1982;17(2):275-280. View abstract.

Kushnir, S. L., Ratner, J. T., and Gregoire, P. A. Multiple nutrients in the treatment of Alzheimer's disease. J Am Geriatr.Soc 1987;35(5):476-477. View abstract.

Lampe, T. H., Norris, J., Risse, S. C., Owen-Williams, E., and Keenan, T. Therapeutic Potential of Thyrotropin-Releasing Hormone (TRH) and Lecithin Co-administration in Alzheimer's Disease. Neurobiology of Aging 1990;11:346.

Levin, H. S. and Peters, B. H. Long-term administration of oral physostigmine and lecithin improve memory in Alzheimer's disease. Ann.Neurol. 1984;15(2):210. View abstract.

Levy, R., Little, A., Chuaqui, P., and Reith, M. Early results from double-blind, placebo controlled trial of high dose phosphatidylcholine in Alzheimer's disease. Lancet 4-30-1983;1(8331):987-988. View abstract.

Lieber, C. S., DeCarli, L. M., Mak, K. M., Kim, C. I., and Leo, M. A. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology 1990;12(6):1390-1398. View abstract.

McLachlan, D. R., Smith, W. L., and Kruck, T. P. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum. Ther.Drug Monit. 1993;15(6):602-607. View abstract.

Melancon, S. B., Dallaire, L., Potier, M., Vanasse, M., Marois, P., Geoffroy, G., and Barbeau, A. Oral lecithin and linoleic acid in Friedreich's ataxia: I. Design of the study, material and methods. Can.J Neurol.Sci 1982;9(2):151-154. View abstract.

Nair, M. P., Kudchodkar, B. J., Pritchard, P. H., and Lacko, A. G. Purification of recombinant lecithin: cholesterol acyltransferase. Protein Expr.Purif. 1997;10(1):38-41. View abstract.

Pentland, B., Martyn, C. N., Steer, C. R., and Christie, J. E. Lecithin treatment in Friedreich's ataxia. Br Med J (Clin Res Ed) 4-11-1981;282(6271):1197-1198. View abstract.

Perez-Cruet, J., Menendez, I., Alvarez-Ghersi, J., Falcon, J. R., Valderrabano, O., Castro-Urrutia, E. C., Ifarraguerri, C., and Perez, L. L. Double-blind study of lecithin in the treatment of persistent tardive dyskinesia. Bol.Asoc.Med P.R. 1981;73(11):531-537. View abstract.

Perryman, K. M. and Fitten, L. J. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. Life Sci 1993;53(6):479-486. View abstract.

Perryman, K. M. and Fitten, L. J. Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol. 1991;4(3):127-133. View abstract.

Peters, B. H. and Levin, H. S. Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol. 1979;6(3):219-221. View abstract.

Sannita, W. G., Balestra, V., Rosadini, G., Salama, M., and Timitilli, C. Quantitative EEG and neuropsychological effects of piracetam and of the association piracetam-lecithin in healthy volunteers. Neuropsychobiology 1985;14(4):203-209. View abstract.

Smith, R. C., Vroulis, G., Johnson, R., and Morgan, R. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. Psychopharmacol.Bull. 1984;20(3):542-545. View abstract.

Sorgatz, H. [Effect of lecithin on health status and concentration. Placebo-controlled double-blind study in healthy probands]. Fortschr Med 4-10-1988;106(11):233-236. View abstract.

Stoll, A. L., Sachs, G. S., Cohen, B. M., Lafer, B., Christensen, J. D., and Renshaw, P. F. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol.Psychiatry 9-1-1996;40(5):382-388. View abstract.

Thal, L. J., Fuld, P. A., Masur, D. M., and Sharpless, N. S. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol. 1983;13(5):491-496. View abstract.

Thal, L. J., Masur, D. M., Sharpless, N. S., Fuld, P. A., and Davies, P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog.Neuropsychopharmacol.Biol.Psychiatry 1986;10(3-5):627-636. View abstract.

Tudorache, B., Lupulescu, R., Dutan, I., and Sarbulescu, A. Assessment of various psychopharmacological combinations in the treatment of presenile and senile primary degenerative dementia. Rom.J Neurol.Psychiatry 1990;28(4):277-294. View abstract.

Tuzhilin, S. A., Dreiling, D. A., Narodetskaja, R. V., and Lukash, L. K. The treatment of patients with gallstones by lecithin. Am J Gastroenterol. 1976;65(3):231-235. View abstract.

Uney, J. B., Jones, G. M., Rebeiro, A., and Levy, R. The effect of long-term high dose lecithin on erythrocyte choline transport in Alzheimer patients. Biol.Psychiatry 3-15-1992;31(6):630-633. View abstract.

Vida, S., Gauthier, L., and Gauthier, S. Canadian collaborative study of tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer's disease: effect on mood. Can.J Psychiatry 1989;34(3):165-170. View abstract.

Vinarova, E. and Vinar, O. Lecithin in a Psychiatric Out-patient Clinic. Activ nerv sup (Prana) 1987;29(3):219-221.

Volz, H. P., Hehnke, U., and Hauke, W. [Improvement in quality of life in the elderly. Results of a placebo-controlled study on the efficacy and tolerability of lecithin fluid in patients with impaired cognitive functions]. MMW Fortschr Med 12-9-2004;146(Suppl 3-4):99-106. View abstract.

von Allworden, H. N., Horn, S., Kahl, J., and Feldheim, W. The influence of lecithin on plasma choline concentrations in triathletes and adolescent runners during exercise. Eur.J.Appl.Physiol Occup.Physiol 1993;67(1):87-91. View abstract.

Vroulis, G. A., Smith, R. C., Brinkman, S., Schoolar, J., and Gordon, J. The effects of lecithin on memory in patients with senile dementia of the Alzheimer's type [proceedings]. Psychopharmacol Bull 1981;17(1):127-128. View abstract.

Vroulis, G., Smith, R. C., Schoolar, J. C., Dahlen, G., Katz, E., and Misra, C. H. Reduction of cholesterol risk factors by lecithin in patients with Alzheimer's disease. Am J Psychiatry 1982;139(12):1633-1634. View abstract.

Weintraub, S., Mesulan, M. M., Auty, R., Baratz, R., Cholakos, B. N., Kapust, L., Ransil, B., Tellers, J. G., Albert, M. S., LoCastro, S., and Moss, M. Lecithin in the treatment of Alzheimer's disease. Arch Neurol. 1983;40(8):527-528. View abstract.

Wurtman, R. J., Hirsch, M. J., and Growdon, J. H. Lecithin consumption raises serum-free-choline levels. Lancet 7-9-1977;2(8028):68-69. View abstract.

Zhang, A. Q., Mitchell, S. C., and Smith, R. L. Dietary precursors of trimethylamine in man: a pilot study. Food Chem.Toxicol. 1999;37(5):515-520. View abstract.

Andrioli G, Carletto A, Guarini P, et al. Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion. Thromb Haemost 1999;82:1522-7. View abstract.

Brinkman SD, Smith RC, Meyer JS, et al. Lecithin and memory training in suspected Alzheimer's disease. J Gerontol 1982;37:4-9. View abstract.

Buchman AL, Awal M, Jenden D, et al. The effect of lecithin supplementation on plasma choline concentrations during a marathon. J Am Coll Nutr 2000;19:768-70. View abstract.

Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. Gastroenterology 1992;102:1363-70. View abstract.

Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine. BMJ 1990;300:495-9. View abstract.

Cohen BM, Lipinski JF, Altesman RI. Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J Psychiatry 1982;139:1162-4. View abstract.

Conte A, Ronca G, Petrini M, et al. Effect of lecithin on epicutaneous absorption of diclofenac epolamine. Drugs Exp Clin Res 2002;28:249-55. View abstract.

Domino EF, May WW, Demetriou S, et al. Lack of clinically significant improvement of patients with tardive dyskinesia following phosphatidylcholine therapy. Biol Psychiatry 1985;20:1189-96. View abstract.

Drachman DA, Glosser G, Fleming P, et al. Memory decline in the aged: treatment with lecithin and physostigmine. Neurology 1982;32:944-50. View abstract.

Electronic Code of Federal Regulations. Title 21, Chapter 1, Subchapter B, Part 184: Direct food substances affirmed as Generally Recognized as Safe. Subpart B - listing of specific substances affirmed as GRAS. Sec. 184.1400 Lecithin. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1400

Etienne P, Dastoor D, Gauthier S, et al. Alzheimer disease: lack of effect of lecithin treatment for 3 months. Neurol 1981;31:1552-4. View abstract.

Evans M, Njike VY, Hoxley M, et al. Effect of soy isoflavone protein and soy lecithin on endothelial function in healthy postmenopausal women. Menopause 2007;14:141-9. View abstract.

Facts and Comparisons, loose leaf edition. St. Louis, MO: Wolters Kluwer Co., 1999.

Fioravanti A, Cicero MR, Nerucci F, et al. Double-blind controlled clinical study of the efficacy and tolerability of diclofenac-N-(2-hydroxyethyl)-pyrrolidine lecithin gel compared with diclofenac-N-(2-hydroxyethyl)-pyrrolidine gel in patients with peri and extraarticular inflammatory diseases. Drugs Exp Clin Res 1999;25:235-40. View abstract.

Fisman M, Merskey H, Helmes E, et al. Double blind study of lecithin in patients with Alzheimer's disease. Can.J Psychiatry 1981;26:426-28. View abstract.

Fitten LJ, Perryman KM, Gross PL, et al. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry 1990;147:239-42. View abstract.

Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (2000). Washington, DC: National Academy Press, 2000. Available at: https://books.nap.edu/books/0309065542/html/.

Gelenberg AJ, Dorer DJ, Wojcik JD, et al. A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry 1990;51:149-53. View abstract.

Goldberg AC, Ostlund RE, Bateman JH, et al. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs.Am J Cardiol. 2-1-2006;97:376-79. View abstract.

Gremaud G, Dalan E, Piguet C, et al. Effects of non-esterified stanols in a liquid emulsion on cholesterol absorption and synthesis in hypercholesterolemic men. Eur J Nutr 2002;41:54-60. View abstract.

Growdon JH, Corkin S, Huff FJ, et al. Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 1986;7:269-76. View abstract.

Guan R, Ho KY, Kang JY, et al. The effect of polyunsaturated phosphatidyl choline in the treatment of acute viral hepatitis. Aliment Pharmacol Ther 1995;9:699-703. View abstract.

Harris CM, Dysken MW, Fovall P, Davis JM. Effect of lecithin on memory in normal adults. Am J Psychiatry 1983;140:1010-2. View abstract.

Hebel SK, ed. Drug Facts and Comparisons. 52nd ed. St. Louis: Facts and Comparisons, 1998.

Hellhammer J, Fries E, Buss C, et al. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. Stress. 2004;7:119-26. View abstract.

Heyman A, Schmechel D, Wilkinson W, et al. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease. J Neural Transm Suppl 1987;24:279-86. View abstract.

Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2000;4:CD001015. View abstract.

Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2003;(3):CD001015. View abstract.

Holan KR, Holzbach RT, Hsieh JY, et al. Effect of oral administration of essential phospholipid, beta-glycerophosphate, and linoleic acid on biliary lipids in patients with cholelithiasis. Digestion 1979;19:251-8. View abstract.

Jenike MA, Albert MS, Heller H, et al. Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease. J Clin Psychiatry 1986;47:249-51. View abstract.

Jenkins PJ, Portmann BP, Eddleston AL, Williams R. Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver 1982;2:77-81. View abstract.

Kapen S, Fleming PD, Drachman DA. Cholinergic enhancement and REM sleep latency in the aged: lecithin does not reproduce physostigmine effect. Neurology 1986;36:1079-83. View abstract.

Kraft JN, Lynde CW. Moisturizers: what they are and a practical approach to product selection. Skin Ther Lett 2005;10(5):1-8.

Krag A, Israelsen H, von Ryberg B, et al. Safety and efficacy of Profermin® to induce remission in ulcerative colitis. World J Gastroenterol 2012;18(15):1773-80.View abstract.

Krag A, Munkholm P, Israelsen H, von Ryberg B, Andersen KK, Bendtsen F. Profermin is efficacious in patients with active ulcerative colitis--a randomized controlled trial. Inflamm Bowel Dis. 2013;19(12):2584-92. View abstract.

Ladd SL, Sommer SA, LaBerge S, Toscano W. Effect of phosphatidylcholine on explicit memory. Clin Neuropharmacol 1993;16:540-9. View abstract.

Levin HS, Peters BH, Kalisky Z, et al. Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients. Cent.Nerv.Syst.Trauma 1986;3:333-42. View abstract.

Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:736-42. View abstract.

Mahler P, Mahler F, Duruz H, et al. Double-blind, randomized, controlled study on the efficacy and safety of a novel diclofenac epolamine gel formulated with lecithin for the treatment of sprains, strains and contusions. Drugs Exp Clin Res 2003;29:45-52. View abstract.

Maltby N, Broe GA, Creasey H, et al. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double-blind trial. BMJ 1994;308:879-83. View abstract.

Melancon SB, Vanasse M, Geoffroy G, et al. Oral lecithin and linoleic acid in Friedreich's ataxia: II. Clinical results. Can.J Neurol.Sci 1982;9:155-64. View abstract.

Oosthuizen W, Vorster HH, Vermaak WJ, et al. Lecithin has no effect on serum lipoprotein, plasma fibrinogen and macro molecular protein complex levels in hyperlipidaemic men in a double-blind controlled study. Eur J Clin Nutr 1998;52:419-24. View abstract.

Ostlund RE Jr, Spilburg CA, Stenson WF. Sitostanol administered in lecithin micelles potently reduces cholesterol absorption in humans. Am J Clin Nutr 1999;70:826-31. View abstract.

Palm M, Moneret-Vautrin DA, Kanny G, et al. Food allergy to egg and soy lecithins. Allergy 1999;54:1116-7. View abstract.

Pomara N, Domino EF, Yoon H, et al. Failure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease. J Clin Psychiatry 1983;44:293-5. View abstract.

Sidhu N, Davies S, Nadarajah A, et al. Oral choline supplementation for postoperative pain. Br J Anaesth 2013;111(2):249-55. View abstract .

Simons LA, Hickie JB, Ruys J. Treatment of hypercholesterolaemia with oral lecithin. Aust N Z J Med 1977;7:262-6. View abstract.

Sourkes TL. The discovery of lecithin, the first phospholipid. Bull Hist Chem. 2004;29(1):9-15.

Spilburg CA, Goldberg AC, McGill JB, et al. Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol. J Am Diet Assoc 2003;103:577-81. View abstract.

Tweedy JR and Garcia CA. Lecithin treatment of cognitively impaired Parkinson's patients. Eur J Clin Invest 1982;12:87-90. View abstract.

Volavka J, O'Donnell J, Muragali R,et al. Lithium and lecithin in tardive dyskinesia: an update. Psychiatry Res 1986;19:101-4. View abstract.

Wade A, Weller PJ, eds. Handbook of Pharmaceutical Excipients. 2nd ed. Washington, DC: Am Pharmaceutical Assn, 1994.

Wu Y, Wang T. Soybean lecithin fractionation and functionality. JAOCS 2003;80(4):319-326.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.